Apollo Hospitals Enterprise LtdNSE: APOLLOHOSP
Open the Apollo Hospitals Enterprise Ltd page
Follow Apollo Hospitals Enterprise LtdFree account. Get a note when Apollo Hospitals Enterprise Ltd files.
Q1 FY27 results analysis · August 12, 2026

Apollo Hospitals Q1 FY27 Results Analysis: Revenue Surges 21%, EBITDA Margin Expands 90 bps (APOLLOHOSP)

+34.2%PAT year on year, Rs. 580.70 Cr
Cofacto ResearchPublished August 12, 20262 min readPositive read
Quick summary

Apollo Hospitals Enterprise Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 7,043.50 Cr (+20.60% YoY) and PAT growth of +34.20% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateAugust 12, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 7,043.50 Cr (+20.60% YoY)
PAT (Q1)Rs. 580.70 Cr (+34.20% YoY)
EBITDA margin15.50% (+90 bps YoY)
EPS (Q1)Rs. 40.39 (+34.20% YoY)
Market capRs. 123,604.60 Cr
CMPRs. 8,597.00

Quarter Snapshot

Revenue crossed Rs.7,000 Cr with broad-based growth of 20.6% YoY, while EBITDA margins expanded 90 bps YoY to 15.5%. Digital Health EBIT more than doubled, and occupancy improved to 70%, indicating strong operational momentum. New hospital losses are within guidance, and the announced divestiture and demerger provide catalysts for unlocking value.

Key Investment Insights

Key Positives

  • Revenue grew 20.6% YoY to Rs.7,043.5 Cr, a record quarterly print.
  • EBITDA grew 28.2% YoY to Rs.1,092.1 Cr, with margin expanding 90 bps YoY to 15.5%.
  • PAT attributable to owners grew 34.2% YoY to Rs.580.7 Cr.
  • Healthcare Services occupancy improved to 70% from 65% YoY, with revenue growing 22% YoY.
  • Digital Health and Pharmacy EBIT more than doubled YoY to Rs.152.3 Cr, margin improving to 5.1%.
  • Retail Health EBIT surged 219.7% YoY to Rs.22.7 Cr, with margin improving to 4.5%.
  • Standalone revenue grew 22.5% YoY, and subsidiary contribution rose 55.3% YoY.

Risk Factors

  • New hospitals recorded an EBITDA loss of Rs.38 Cr in Q1, though within the annual guidance of ≤Rs.150 Cr.
  • Other expenses grew 26.7% YoY, outpacing revenue growth, partly due to new hospital pre-operative costs.
  • HealthCo annualized revenue run-rate of ~Rs.11,908 Cr remains far from the Rs.25,000 Cr target for Q4FY27, requiring aggressive growth.

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.